1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Medicare Price Negotiations: Competitors’ Net Prices, Clinical Benefit Are ‘Starting Point’ For Initial Offer

 
• By Sarah Karlin-Smith

CMS chose the prices of therapeutic alternatives and these competitors’ comparative benefits as the ‘foundation and starting point’ for setting an initial offer for drugs subject to negotiation, ahead of other factors Congress laid out it could consider that are more singularly focused on the specific drug at issue.

boxing gloves
Competitor pricing may influence CMS drug price negotiations more than manufacturer-provided data, per new guidance • Source: Shutterstock

The net prices and clinical benefit of therapeutic alternatives will be critical starting points for the Centers for Medicare and Medicaid Services as it looks to craft initial offers for the first set of drugs selected for US government price negotiations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access